DK2074108T3 - Renin-inhibitorer - Google Patents

Renin-inhibitorer

Info

Publication number: DK2074108T3
Authority: DK; Denmark
Prior art keywords: renin inhibitors; renin; inhibitors
Prior art date: 2006-09-18

Application number

DK07838381.7T

Other languages

English (en)

Inventor

John J Baldwin

David A Claremon

Colin M Tice

Lawrence W Dillard

Alexey V Ishchenko

Jing Yuan

Zhenrong Xu

Gerard Mcgeehan

Wei Zhao

Robert D Simpson

Suresh B Singh

Patrick T Flaherty

Lanqi Jia

Salvacion Cacatian

Original Assignee

Vitae Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-18

Filing date

2007-09-18

Publication date

2013-03-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2074108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-18 Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc

2013-03-11 Application granted granted Critical

2013-03-11 Publication of DK2074108T3 publication Critical patent/DK2074108T3/da

Links

239000002461 renin inhibitor Substances 0.000 title 1
229940086526 renin-inhibitors Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

DK07838381.7T 2006-09-18 2007-09-18 Renin-inhibitorer DK2074108T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84529106P	2006-09-18	2006-09-18
PCT/US2007/020164 WO2008036247A1 (en)	2006-09-18	2007-09-18	Renin inhibitors

Publications (1)

Publication Number	Publication Date
DK2074108T3 true DK2074108T3 (da)	2013-03-11

Family

ID=38786973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07838381.7T DK2074108T3 (da)	2006-09-18	2007-09-18	Renin-inhibitorer

Country Status (22)

Country	Link
US (2)	US8198453B2 (da)
EP (2)	EP2074108B3 (da)
JP (1)	JP5331695B2 (da)
KR (1)	KR20090064582A (da)
CN (1)	CN101528723B (da)
AR (1)	AR062797A1 (da)
AU (1)	AU2007297729C1 (da)
BR (1)	BRPI0718460A2 (da)
CA (1)	CA2663263A1 (da)
CL (1)	CL2007002689A1 (da)
DK (1)	DK2074108T3 (da)
ES (1)	ES2400009T7 (da)
HR (1)	HRP20130144T4 (da)
MX (1)	MX2009002740A (da)
NZ (1)	NZ575803A (da)
PE (1)	PE20080843A1 (da)
PL (1)	PL2074108T6 (da)
PT (1)	PT2074108E (da)
RS (1)	RS52679B (da)
SI (1)	SI2074108T1 (da)
TW (1)	TWI403510B (da)
WO (1)	WO2008036247A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5067968B2 (ja)	2004-10-07	2012-11-07	ビテファーマシューティカルズ，インコーポレイテッド	ジアミノアルカンアスパラギン酸プロテアーゼ阻害剤
TWI411607B (zh)	2005-11-14	2013-10-11	Vitae Pharmaceuticals Inc	天門冬胺酸蛋白酶抑制劑
JP2010503682A (ja) *	2006-09-18	2010-02-04	ビテファーマシューティカルズ，インコーポレイテッド	レニン阻害剤としてのピペリジン誘導体
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2167609A1 (en) *	2007-06-20	2010-03-31	Vitae Pharmaceuticals, Inc.	Renin inhibitors
US20100160424A1 (en) *	2007-06-20	2010-06-24	Baldwin John J	Renin inhibitors
US20110160300A1 (en) *	2008-06-20	2011-06-30	Marlys Hammond	Renin Inhibitors and Methods of Use Thereof
US20100010228A1 (en) *	2008-06-26	2010-01-14	Vitae Pharmaceuticals, Inc.	Process for the asymmetric reduction of 3-benzoylpiperidines
AU2009262319A1 (en) *	2008-06-26	2009-12-30	Vitae Pharmaceuticals, Inc.	Salts of methyl 2-((R))-(3-chlorophenyl) ((R)-1-((S)-2- (methylamino)-3((R)-tetrahydro-2H-pyran-3-yl) propylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
AU2016256776B2 (en) *	2009-03-18	2018-04-12	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) *	2009-03-18	2016-08-18	Incarda Therapeutics, Inc	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES2750359T3 (es) *	2009-03-18	2020-03-25	Incarda Therapeutics Inc	Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
IL260335B2 (en)	2016-02-01	2023-10-01	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
JP2020519628A (ja)	2017-05-10	2020-07-02	インカーダセラピューティクス，インコーポレイテッド	肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
IL321589A (en)	2019-08-01	2025-08-01	Incarda Therapeutics Inc	Antiarrhythmic formulation comprising a salt of flecainide
CN117567292B (zh) *	2023-12-01	2026-01-16	江苏宝众宝达药业股份有限公司	一种制备高纯度5-氯-2-甲基苯胺的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3071618A (en)	1956-02-02	1963-01-01	Pfizer & Co C	Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
GB1351761A (en)	1971-02-04	1974-05-01	Wilkinson Sword Ltd	Substituted p-menthane carboxamides and compositions containing them
US4136163A (en)	1971-02-04	1979-01-23	Wilkinson Sword Limited	P-menthane carboxamides having a physiological cooling effect
JPS5115098A (ja)	1974-07-26	1976-02-06	Asahi Chemical Ind	Akurirukeiseniseihinno shorihoho
US4826689A (en)	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en)	1984-10-19	1986-06-10	Shanklin Jr James R	1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en)	1988-04-28	1988-06-02	Ucb Sa	Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr)	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en)	1988-10-13	1990-03-13	Merrell Dow Pharmaceuticals Inc.	Antihistaminic piperidinyl benzimidazoles
IT1227626B (it)	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5539122A (en)	1989-05-23	1996-07-23	Abbott Laboratories	Retroviral protease inhibiting compounds
RU2147875C1 (ru)	1990-05-11	2000-04-27	Пфайзер Инк.	Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
US5821232A (en)	1990-05-11	1998-10-13	Pfizer Inc.	Synergistic therapeutic compositions and methods
DE4018070A1 (de)	1990-06-06	1991-12-12	Bayer Ag	Morpholinoharnstoff-derivate
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
FI932687L (fi)	1990-12-14	1993-06-11	Merrell Dow Pharma	Antiallergiska foereningar
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5552160A (en)	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
WO1993016081A1 (en)	1992-02-13	1993-08-19	Merrell Dow Pharmaceuticals Inc.	Piperidinyl thiacyclic derivatives
AU677783B2 (en)	1992-06-10	1997-05-08	Elan Pharma International Limited	Surface modified nsaid nanoparticles
NZ248813A (en)	1992-11-25	1995-06-27	Eastman Kodak Co	Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en)	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en)	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en)	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en)	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en)	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en)	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en)	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0773921B1 (en)	1994-07-29	1999-12-01	Abbott Laboratories	Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
US6162927A (en)	1994-08-19	2000-12-19	Abbott Laboratories	Endothelin antagonists
US5767144A (en)	1994-08-19	1998-06-16	Abbott Laboratories	Endothelin antagonists
US6946481B1 (en)	1994-08-19	2005-09-20	Abbott Laboratories	Endothelin antagonists
US5585108A (en)	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en)	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en)	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en)	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en)	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en)	1995-02-14	1996-10-01	Nawosystems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en)	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en)	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5622938A (en)	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5534270A (en)	1995-02-09	1996-07-09	Nanosystems Llc	Method of preparing stable drug nanoparticles
US5518738A (en)	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en)	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en)	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en)	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en)	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en)	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en)	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
PL193686B1 (pl)	1995-09-07	2007-03-30	Hoffmann La Roche	Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
EP0983269A4 (en)	1997-05-29	2001-06-27	Lilly Co Eli	PROCESSES USEFUL FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS
WO1999054321A1 (en)	1998-04-21	1999-10-28	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en)	1998-09-25	2002-08-20	Fujisawa Pharmaceutical Co., Ltd.	Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) *	1998-12-02	1999-01-27	Darwin Discovery Ltd	Process
AU2492500A (en)	1999-01-06	2000-07-24	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Aspartic protease inhibitors, compositions, and associated therapeutic methods
JP2000302757A (ja)	1999-04-16	2000-10-31	Shiseido Co Ltd	Ｎ−置換ピペリジン誘導体
AU4344101A (en)	2000-03-21	2001-10-03	Smithkline Beecham Corp	Protease inhibitors
US6900329B2 (en)	2001-03-21	2005-05-31	Schering Corporation	MCH antagonists and their use in the treatment of obesity
GEP20074221B (en)	2001-07-11	2007-10-25	Elan Pharm Inc	N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
RS50504A (sr)	2001-11-08	2007-04-10	Elan Pharmaceuticals Inc.,	Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
AU2003231765B9 (en)	2002-04-26	2010-01-28	Gilead Sciences, Inc.	Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
AU2003238046A1 (en)	2002-06-27	2004-01-19	Actelion Pharmaceuticals Ltd	Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
US7557137B2 (en)	2002-08-05	2009-07-07	Bristol-Myers Squibb Company	Gamma-lactams as beta-secretase inhibitors
WO2004024675A1 (en)	2002-09-10	2004-03-25	Pharmacia & Upjohn Company Llc	Substituted aminoethers for the treatment of alzheimer's disease
WO2005049027A2 (en)	2003-11-03	2005-06-02	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
JP2007513107A (ja) *	2003-12-05	2007-05-24	アクテリオン　ファマシューティカルズ　リミテッド	ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体
US20070093492A1 (en)	2004-03-09	2007-04-26	Weir-Torn Jiaang	Pyrrolidine derivatives
JP2008510726A (ja)	2004-08-20	2008-04-10	エントレメッドインコーポレイテッド	プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
JP5067968B2 (ja) *	2004-10-07	2012-11-07	ビテファーマシューティカルズ，インコーポレイテッド	ジアミノアルカンアスパラギン酸プロテアーゼ阻害剤
CA2595986A1 (en) *	2005-01-28	2006-08-03	Actelion Pharmaceuticals Ltd	7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension
JP2008528691A (ja) *	2005-02-02	2008-07-31	ビテファーマシューティカルズ，インコーポレイテッド	レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン
DK1882684T3 (da)	2005-05-19	2015-01-05	Astellas Pharma Inc	Pyrrolidinderivat eller salt deraf
TWI411607B (zh)	2005-11-14	2013-10-11	Vitae Pharmaceuticals Inc	天門冬胺酸蛋白酶抑制劑
WO2007117557A2 (en)	2006-04-05	2007-10-18	Vitae Pharmaceuticals, Inc.	Diaminopropanol renin inhibitors
JP2010503682A (ja)	2006-09-18	2010-02-04	ビテファーマシューティカルズ，インコーポレイテッド	レニン阻害剤としてのピペリジン誘導体
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US20100160424A1 (en)	2007-06-20	2010-06-24	Baldwin John J	Renin inhibitors
EP2167609A1 (en)	2007-06-20	2010-03-31	Vitae Pharmaceuticals, Inc.	Renin inhibitors
US7773441B2 (en) *	2008-06-18	2010-08-10	Micron Technology, Inc.	Memory malfunction prediction system and method
US20110160300A1 (en)	2008-06-20	2011-06-30	Marlys Hammond	Renin Inhibitors and Methods of Use Thereof
AU2009262319A1 (en)	2008-06-26	2009-12-30	Vitae Pharmaceuticals, Inc.	Salts of methyl 2-((R))-(3-chlorophenyl) ((R)-1-((S)-2- (methylamino)-3((R)-tetrahydro-2H-pyran-3-yl) propylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

2007
- 2007-09-14 CL CL200702689A patent/CL2007002689A1/es unknown
- 2007-09-17 PE PE2007001252A patent/PE20080843A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104098A patent/AR062797A1/es unknown
- 2007-09-17 TW TW096134810A patent/TWI403510B/zh not_active IP Right Cessation
- 2007-09-18 SI SI200731161T patent/SI2074108T1/sl unknown
- 2007-09-18 RS RS20130064A patent/RS52679B/sr unknown
- 2007-09-18 WO PCT/US2007/020164 patent/WO2008036247A1/en not_active Ceased
- 2007-09-18 AU AU2007297729A patent/AU2007297729C1/en not_active Ceased
- 2007-09-18 CA CA002663263A patent/CA2663263A1/en not_active Withdrawn
- 2007-09-18 PL PL07838381T patent/PL2074108T6/pl unknown
- 2007-09-18 PT PT78383817T patent/PT2074108E/pt unknown
- 2007-09-18 MX MX2009002740A patent/MX2009002740A/es active IP Right Grant
- 2007-09-18 CN CN2007800391198A patent/CN101528723B/zh not_active Expired - Fee Related
- 2007-09-18 ES ES07838381T patent/ES2400009T7/es active Active
- 2007-09-18 KR KR1020097007791A patent/KR20090064582A/ko not_active Ceased
- 2007-09-18 DK DK07838381.7T patent/DK2074108T3/da active
- 2007-09-18 EP EP07838381.7A patent/EP2074108B3/en active Active
- 2007-09-18 HR HRP20130144TT patent/HRP20130144T4/hr unknown
- 2007-09-18 JP JP2009528331A patent/JP5331695B2/ja not_active Expired - Fee Related
- 2007-09-18 US US12/311,012 patent/US8198453B2/en not_active Expired - Fee Related
- 2007-09-18 BR BRPI0718460-3A patent/BRPI0718460A2/pt not_active IP Right Cessation
- 2007-09-18 NZ NZ575803A patent/NZ575803A/en not_active IP Right Cessation
- 2007-09-18 EP EP11186691.9A patent/EP2581366A1/en not_active Withdrawn
2012
- 2012-05-11 US US13/469,562 patent/US8580823B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101528723B (zh)	2013-04-10
MX2009002740A (es)	2009-06-26
ES2400009T3 (es)	2013-04-05
CL2007002689A1 (es)	2008-04-18
AU2007297729C1 (en)	2012-02-02
PL2074108T6 (pl)	2013-11-29
PL2074108T3 (pl)	2013-05-31
WO2008036247A1 (en)	2008-03-27
HRP20130144T1 (en)	2013-03-31
PT2074108E (pt)	2013-03-07
WO2008036247A8 (en)	2008-06-26
KR20090064582A (ko)	2009-06-19
HK1129115A1 (en)	2009-11-20
EP2074108B1 (en)	2012-11-21
JP5331695B2 (ja)	2013-10-30
JP2010503684A (ja)	2010-02-04
US8580823B2 (en)	2013-11-12
TWI403510B (zh)	2013-08-01
ES2400009T7 (es)	2013-11-18
AU2007297729B2 (en)	2011-07-28
TW200829574A (en)	2008-07-16
US20120225906A1 (en)	2012-09-06
US8198453B2 (en)	2012-06-12
CN101528723A (zh)	2009-09-09
US20090312369A1 (en)	2009-12-17
EP2581366A1 (en)	2013-04-17
RS52679B (sr)	2013-06-28
PE20080843A1 (es)	2008-08-11
AR062797A1 (es)	2008-12-03
BRPI0718460A2 (pt)	2013-12-03
NZ575803A (en)	2011-11-25
EP2074108B3 (en)	2013-06-26
AU2007297729A1 (en)	2008-03-27
EP2074108A1 (en)	2009-07-01
HRP20130144T4 (hr)	2013-10-25
CA2663263A1 (en)	2008-03-27
SI2074108T1 (sl)	2013-04-30

Publication	Publication Date	Title
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0807547A2 (pt)	2014-06-17	Inibidores de aspartil protease hetercíclicos
BRPI0719204A2 (pt)	2014-03-04	Inibidores de hdac
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2402317T3 (da)	2013-10-07	DGAT-inhibitor
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
EP2305306A4 (en)	2012-08-29	NEURO INVASION INHIBITOR
HRP20130144T1 (en)	2013-03-31	Renin inhibitors
BRPI0918564A2 (pt)	2015-12-01	inibidores
EP2229363A4 (en)	2010-12-15	Renin Inhibitors
BRPI0720547A2 (pt)	2014-05-06	Inibidores de metaloprotease derivada de heterocíclico
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
EP2162436A4 (en)	2010-08-04	NEW CASE OF RENININHIBITORS
FR2911341B1 (fr)	2013-01-11	Inhibiteur de corrosion
DE112007003149A5 (de)	2009-09-24	Spannfutter
DK1991718T3 (da)	2013-10-28	Korrosionsinhibitorer
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
DE502006004094D1 (de)	2009-08-06	Bohrfutter
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
BRPI0918966A2 (pt)	2015-12-01	inibidores de protease